Healthcare companies are always looking to utilize M&A as a means to drive shareholder value despite market cycles and uncertainties.
As our track record demonstrates, we partner with our clients to deliver deep sector insights and broad connectivity to provide trusted advice.
Recent Transactions
See all transactions
UNDISCLOSED
UNDISCLOSED
UNDISCLOSED
UNDISCLOSED
UNDISCLOSED
Up to $213 Million
Up to $291 Million
UNDISCLOSED
UNDISCLOSED
UNDISCLOSED
UNDISCLOSED
UNDISCLOSED
Team
Leerink Partners’ M&A Advisory team is led by senior, experienced professionals with over 20 years’ experience and long-term relationships with healthcare consolidators. Our team is singularly focused on our clients’ success and value-creating transactions.
Banking Team
Dan Lepanto
Senior Managing Director, Healthcare Mergers & Acquisitions
Dan Lepanto is a Senior Managing Director at Leerink Partners and leads the Biopharma Mergers & Acquisitions team.
Prior to joining the firm in 2008, Dan spent 10 years at Cowen and Company where he executed a range of biopharma M&A transactions. Dan began his career in the Mergers & Acquisitions group at Wasserstein Perella. He has advised on a number of biopharma and health care transactions over the span of his career including the sale of Dicerna to Novo Nordisk, the sale of Dermira to Eli Lilly, the sale of NPS to Shire, the sale of Cynosure to Hologic, the sale of TKT to Shire, the sale of GelTex to Genzyme, the merger of Total Renal Care with Renal Treatment Centers and the acquisition of Vivra by Gambro.
He earned his B.S. in Finance with High Honors from Pennsylvania State University.